---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-004132"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-01-16T23:59:59+00:00"
generated_at: "2026-05-28T00:08:13.447067+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Quoin reports positive QRX003 data in Netherton Syndrome: IGA improves from severe to mild after 6 weeks

## Summary
- IGA score improved from 'severe' at baseline to 'mild' after six weeks of twice-daily QRX003 dosing.
- After 12 days of dosing, IGA was 'mild-moderate'; full 6-week data confirms continued improvement.
- Subject transitioned from 20% BSA treatment to whole-body application based on positive results.
- No adverse events or safety concerns reported for this subject, consistent with prior studies.
- Data from ongoing 12-week Investigator Pediatric Study supports QRX003's potential in Netherton Syndrome.

## SEC filing metadata
- accession: 0001104659-25-004132
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925004132/0001104659-25-004132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925004132/tm253523d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-004132
- JSON: https://secwatch.observer/filing/0001104659-25-004132.json
- Plain text: https://secwatch.observer/filing/0001104659-25-004132.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.